Cite
MLA Citation
André Heinen et al.. “Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis?.” Rheumatology, vol. 60, 2021, pp. e136–e138. http://access.bl.uk/ark:/81055/vdc_100124372737.0x000026